Clinical Research Papers:

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer

Coureche Guillaume Kaderbhai, Romain Boidot, Françoise Beltjens, Sandy Chevrier, Laurent Arnould, Laure Favier, Aurélie Lagrange, Bruno Coudert and François Ghiringhelli _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:24860-24870. https://doi.org/10.18632/oncotarget.8391

Metrics: PDF 1275 views  |   HTML 2110 views  |   ?  


Coureche Guillaume Kaderbhai1,*, Romain Boidot2,3,4,*, Françoise Beltjens3, Sandy Chevrier3,4, Laurent Arnould3,4, Laure Favier1, Aurélie Lagrange1, Bruno Coudert1,* and François Ghiringhelli1,2,3,4,*

1 Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France

2 INSERM, U866, Faculté de Médecine, Université de Bourgogne and Centre Georges François Leclerc, Dijon, France

3 Department of Biology and Pathology of Tumors, Centre Georges-François Leclerc, Dijon, France

4 Platform of Transfer in Cancer Biology, Centre Georges-François Leclerc, Dijon, France

* These authors have contributed equally to this work

Correspondence to:

Bruno Coudert, email:

François Ghiringhelli, email:

Keywords: precision medicine, lung cancer, NGS, clinical research

Received: February 04, 2016 Accepted: March 16, 2016 Published: March 26, 2016


Advances in Next Generation Sequencing (NGS) technologies have improved the ability to detect potentially targetable mutations. However, the integration of NGS into clinical management in an individualized manner remains challenging. In this single-center observational study, we performed a dedicated NGS panel studying 41 cancer-related genes in 50 consecutive patients with metastatic non-small-cell lung cancer between May 2012 and October 2014. Molecular analysis could be performed in 48 patients with a good quality check. One hundred and thirty-three mutations, whose twenty-four unique mutations, were detected. At least one mutation was found in 46 patients. In 58% of cases, the Molecular Tumor Board (MTB) was able to recommend treatment with a targeted agent based on the evaluation of the tumor genetic profile and treatment history. Nine patients (18%) were subsequently treated with a MTB-recommended targeted therapy; four patients experienced a clinical benefit with a partial response or stabilization lasting more than 4 months. In this case series involving patients with metastatic non-small cell lung cancer, we show that including integrative clinical sequencing data into routine clinical management was feasible and could impact on patient therapeutic proposal.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8391